← Research status explorer
Ignite / Metabolic
MOTS-c
Current research status
Phase 2a
Early clinical investigation
Preclinical
Phase 1
Phase 2
Phase 3
Approved Molecule*
Overview
MOTS-c is a mitochondrial-derived peptide studied for effects on metabolic regulation and insulin sensitivity. Early-phase human trials, including Phase 2a investigations, have begun evaluating its safety and pharmacokinetics, though its clinical program is considerably smaller and earlier-stage than the approved GLP-1/GIP therapies on this list. Most of the mechanistic evidence for MOTS-c still comes from cellular and animal research.
Last reviewed: September 2026
